Jerusalem-Based Shavit Capital Raises $100 Million for Fifth Fund

Jerusalem-based investment firm Shavit Capital has closed a $100 million in commitments for its fifth fund, the firm announced Wednesday. The firm did not disclose its limited partners, but stated these include “leading financial institutions from the U.S., Asia, and Israel, as well as owners and senior managers of leading investment banks and multi-billion dollar hedge funds.”

With Over $400 million under management, Shavit specializes in late-stage life sciences investments, leading rounds of $20 million to $60 million. While the firm’s previous funds focused on companies gearing towards a Nasdaq initial public offering, Shavit stated its current fund will also include companies looking to list in other markets, such as Europe, Canada, Australia, and Hong Kong.

Shavit’s portfolio includes companies like Jerusalem-headquartered cellular and immune therapies company Gamida Cell Ltd., which raised $50 million on its Nasdaq IPO last week; Jerusalem-based Brainsway Ltd., which develops non-invasive medical devices to treat brain disorders like depression and PTSD; and controlled drug release company Polypid Ltd., which backtracked on its Nasdaq IPO in March.